Anika Therapeutics, Inc. ANIK
19.45 USD +0.04 (+0.21%)
At closeNov 3, 2026, 4:00 PM EST
19.45 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
19.08 Day range 21.55
9.01 52-week range 22.88
- YTD
- +102.39%
- 1 year
- +98.07%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 26.50 +36.2% upside
Now 19.45
- Target (low)
- 25.00
- Target (mean)
- 26.50
- Target (high)
- 28.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 2
- 2 months ago 2
- 3 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.09 | 0.09 – 0.09 | 0.05 | +80.0% | 29.00M | -32.5% | 1 |
| Next quarter | 0.10 | 0.10 – 0.10 | 0.09 | +11.1% | 28.13M | -30.6% | 1 |
| Current year | 0.10 | 0.10 – 0.10 | -0.30 | +133.3% | 150.20M | -9.9% | 1 |
| Next year | 0.47 | 0.47 – 0.47 | 0.10 | +370.0% | 114.50M | -23.8% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Oct 22, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Aug 9, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| May 29, 2024 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| May 9, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Mar 14, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Mar 14, 2024 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Jan 3, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Nov 3, 2023 | Barrington Research | Maintained | Outperform | Outperform |
| Aug 14, 2023 | Barrington Research | Upgrade | Market Perform | Outperform |
| Aug 10, 2023 | Stephens & Co. | Maintained | Equal-Weight | Equal-Weight |
| May 31, 2023 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Apr 14, 2023 | Stephens & Co. | Reiterated | — | Equal-Weight |
| Mar 7, 2023 | Barrington Research | Downgrade | Outperform | Market Perform |
| Nov 9, 2022 | Barrington Research | Upgrade | Market Perform | Outperform |
| Mar 9, 2022 | Stephens & Co. | Downgrade | Overweight | Equal-Weight |
| Nov 16, 2021 | Stephens & Co. | Initiated | — | Overweight |
| Jul 16, 2021 | UBS | Initiated | — | Neutral |
| Dec 16, 2020 | Barrington Research | Upgrade | Market Perform | Outperform |
| Jan 21, 2020 | Sidoti & Co. | Upgrade | Neutral | Buy |
| Nov 5, 2019 | BWS Financial | Initiated | — | Sell |
| Sep 23, 2019 | First Analysis | Downgrade | Strong Buy | Outperform |
| Feb 22, 2019 | Sidoti & Co. | Downgrade | Buy | Neutral |
| Jul 27, 2018 | Barrington Research | Upgrade | Market Perform | Outperform |
| Jun 20, 2018 | First Analysis | Downgrade | Overweight | Equal-Weight |
| May 4, 2018 | Barrington Research | Upgrade | Market Perform | Outperform |
| Feb 23, 2018 | Barrington Research | Downgrade | Outperform | Market Perform |
| Jan 24, 2018 | First Analysis | Upgrade | Equal-Weight | Overweight |
| Apr 27, 2016 | Northland Capital Markets | Downgrade | Outperform | Market Perform |
| Feb 26, 2016 | Northland Capital Markets | Maintained | — | Outperform |